Perfil da empresa · Healthcare

Royalty Pharma Plc

RPRX · EUA
Indústria
生物制药特许权
Bolsa
EUA
País / Região
USA
Data do IPO
25 de março de 1993
Funcionários
100
Site
www.royaltypharma.com
Preço atual
$56.66
Ao vivo · 5 de outubro de 2026
Compra justa
≤ $40
Entrada com margem de segurança
Pontuação de Crescimento Baillie
50/100
Médio
Buffett Score
58/100
Médio
Valor intrínseco · Faixa em três níveis Preço atual $56.66 Ao vivo · Dentro da faixa de valor intrínseco justo

Faixa de valuation composta · conservador $36–$40 / justo $52–$66 / otimista $84–$90. A $56.66, Dentro da faixa de valor intrínseco justo.

Na publicação $58.41 (20 de setembro de 2026)

Resumo financeiro
Valor de mercadoUS$ 33,03 bi
Receita (TTM)US$ 2,54 bi
EBITDAUS$ 1,56 bi
Margem líquida32,02%
ROE13,97%
P/L (TTM)30,9
P/L projetado29,41
PEG1,34
LPAUS$ 1,85
Dividend yield1,58%
Faixa de 52 semanasUS$ 34,56 – US$ 64,38
Preço-alvo dos analistasUS$ 65,13
Recomendação dos analistas4.5 / 5

Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.

Sobre a empresa

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Contexto

História

Em breveEsta seção está sendo preenchida — volte em breve.

Posição no setor

Em breveEsta seção está sendo preenchida — volte em breve.

Análises sobre este ativo
50/100 Manter Royalty Pharma: $3.254bn of Portfolio Receipts and 48% Deal Share Meet a 24% Expiry Wall by 2030 and a $58.41 Price That Already Pays for the Platform Royalty Pharma is a specialty-finance platform whose loan book is denominated in molecules: it buys contractual percentages of other companies' drug sales, funds late-stage development in exchange for synthetic royalties, and collects near the top of the income statement while somebody else carries the commercial cost. 2025 Portfolio Receipts were $3.254bn against only $288m of cash operating and professional costs, and the company sourced 48% of announced biopharma-royalty transaction value over 2020-2025, but roughly 24% of 2025 Royalty Receipts sits on products whose royalty duration substantially ends by 2030, and hitting the $4.7bn 2030 target needs $2.0-2.5bn of deployment every year. Rating Hold: at $58.41 the shares are near 11.6 times estimated 2026 Portfolio Cash Flow but 19-23 times owner earnings once $1.1-1.4bn of replacement deployment is charged as economic maintenance, above the $46-50 conservative value, so the report waits for $36-40 before committing new capital. Royalty Pharma plcRPRX · EUA生物制药特许权20 de setembro de 2026